Updates in Proteasome Inhibitors for Managing Multiple Myeloma

摘要

Because recent research into novel systemic therapies for multiple myeloma keeps yielding promising results, clinicians are equipped with a wide variety of options for managing multiple myeloma.However,treatingpatientswith relapsed or refractory multiple myeloma remains a challenge, and relying on stan-dard-of-care proteasome inhibitors (Pis) is still an important strategy to consider. Placement of Pis in the multiple myeloma treatment paradigm was the subject of a recent Between The Lines, part of an ongoing series hosted by CancerNetwork? in which experts discuss updates in cancer care.